IMRSQ logo

IMRIS Inc. (IMRSQ) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

IMRIS Inc. (IMRSQ), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 46/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
46/100 AI Puanı

IMRIS Inc. (IMRSQ) Sağlık ve Boru Hattı Genel Bakışı

CEOShalabh Chandra
Çalışanlar121
Halka Arz Yılı2023
SektörHealthcare

IMRIS Inc. provides image-guided therapy solutions, featuring VISIUS Surgical Theatres which integrate MRI, CT, and fluoroscopy into surgical suites. Targeting neurosurgical, spinal, cerebrovascular, and cardiovascular markets, IMRIS aims to improve surgical precision and outcomes through advanced intraoperative imaging, operating with a negative profit margin.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

IMRIS Inc. operates in the niche market of intraoperative imaging solutions, offering a potentially valuable technology with its VISIUS Surgical Theatre. The company's ability to integrate MRI, CT, and fluoroscopy into surgical suites provides a unique selling proposition. However, the company's negative profit margin of -105.2% raises concerns about its financial sustainability. Growth catalysts include potential expansion into new therapeutic areas and geographic markets. The company's high beta of 7.79 indicates significant volatility, reflecting the speculative nature of the stock. Investors should carefully consider the risks associated with the company's financial performance and market position.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • IMRIS Inc. operates with a market capitalization of $0.00B, indicating its small size and potential volatility.
  • The company's Price-to-Earnings (P/E) ratio is -0.00, reflecting its lack of profitability.
  • IMRIS Inc. has a negative profit margin of -105.2%, indicating significant operational challenges.
  • The company's gross margin stands at 34.4%, suggesting some ability to generate revenue from its products and services.
  • IMRIS Inc. exhibits a high beta of 7.79, indicating substantial volatility relative to the market.

Rakipler & Benzerleri

Güçlü Yönler

  • Innovative VISIUS Surgical Theatre technology.
  • Integration of multiple imaging modalities in a single surgical suite.
  • Potential to improve surgical precision and patient outcomes.
  • Service and maintenance contracts provide recurring revenue.

Zayıflıklar

  • Negative profit margin indicates financial instability.
  • High beta suggests significant stock volatility.
  • Limited market capitalization restricts growth potential.
  • Dependence on capital equipment sales can lead to revenue fluctuations.

Katalizörler

  • Ongoing: Potential expansion into new therapeutic areas, such as orthopedic surgery or oncology.
  • Ongoing: Development of new applications for the VISIUS Surgical Theatre.
  • Upcoming: Strategic partnerships with companies in related medical technology fields.
  • Ongoing: Technological advancements in AI and machine learning to enhance imaging capabilities.
  • Ongoing: Growth in service and maintenance contract revenue.

Riskler

  • Ongoing: Negative profit margin raises concerns about financial sustainability.
  • Potential: High beta indicates significant stock volatility.
  • Potential: Competition from established medical imaging and surgical equipment companies.
  • Potential: Regulatory hurdles and lengthy approval processes for new medical devices.
  • Potential: Economic downturns affecting hospital capital expenditure budgets.

Büyüme Fırsatları

  • Expansion into Emerging Markets: IMRIS Inc. has the opportunity to expand its presence in emerging markets, where there is a growing demand for advanced medical technologies. These markets often have less established healthcare infrastructure, presenting an opportunity for IMRIS to introduce its VISIUS Surgical Theatre and establish a strong foothold. The timeline for this expansion would involve market research, regulatory approvals, and strategic partnerships with local hospitals and medical centers. This could significantly increase the company's revenue and market share.
  • Development of New Applications: IMRIS Inc. can explore new applications for its VISIUS Surgical Theatre beyond its current focus on neurosurgical, spinal, cerebrovascular, and cardiovascular markets. This could involve adapting the technology for use in other surgical specialties, such as orthopedic surgery, oncology, or robotic surgery. By expanding its applications, IMRIS can broaden its customer base and increase the demand for its products. The timeline for developing new applications would involve research and development, clinical trials, and regulatory approvals.
  • Strategic Partnerships and Collaborations: IMRIS Inc. can pursue strategic partnerships and collaborations with other companies in the medical technology industry. This could involve partnering with companies that specialize in surgical robotics, medical imaging, or healthcare IT solutions. By collaborating with other companies, IMRIS can leverage their expertise and resources to enhance its product offerings and expand its market reach. The timeline for establishing strategic partnerships would involve identifying potential partners, negotiating agreements, and integrating their technologies into IMRIS's solutions.
  • Focus on Service and Maintenance Contracts: IMRIS Inc. can focus on growing its service and maintenance contract business. These contracts provide a recurring revenue stream and help to build long-term relationships with customers. By offering comprehensive service and maintenance packages, IMRIS can ensure the continued performance and reliability of its VISIUS Surgical Theatres, while also generating a steady stream of revenue. The timeline for growing the service and maintenance business would involve developing attractive service packages, training service technicians, and marketing the benefits of these contracts to customers.
  • Technological Advancements and Innovation: IMRIS Inc. can invest in research and development to further advance its imaging technologies and develop new features for its VISIUS Surgical Theatre. This could involve incorporating artificial intelligence (AI) and machine learning (ML) algorithms to enhance image quality, automate surgical workflows, and provide real-time decision support to surgeons. By staying at the forefront of technological innovation, IMRIS can maintain its competitive advantage and attract new customers. The timeline for technological advancements would involve ongoing research and development efforts, clinical trials, and regulatory approvals.

Fırsatlar

  • Expansion into emerging markets with growing healthcare demand.
  • Development of new applications for VISIUS Surgical Theatre in other surgical specialties.
  • Strategic partnerships with companies in related medical technology fields.
  • Technological advancements in AI and machine learning to enhance imaging capabilities.

Tehditler

  • Competition from established medical imaging and surgical equipment companies.
  • Regulatory hurdles and lengthy approval processes for new medical devices.
  • Economic downturns affecting hospital capital expenditure budgets.
  • Technological obsolescence if competitors develop superior imaging solutions.

Rekabet Avantajları

  • Proprietary VISIUS Surgical Theatre technology integrating multiple imaging modalities.
  • Specialized expertise in intraoperative imaging and image-guided therapy.
  • Established relationships with hospitals and medical centers in key markets.
  • Service and maintenance contracts providing recurring revenue.

IMRSQ Hakkında

Founded in 2005 and based in Winnipeg, Canada, IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions. The company's core offering is the VISIUS Surgical Theatre, an advanced surgical environment that incorporates intraoperative imaging technologies such as magnetic resonance imaging (MRI), computed tomography (CT), and fluoroscopy directly into the operating room (OR). This integration allows clinicians to visualize the surgical site in real-time, enhancing precision and facilitating informed decision-making during complex procedures. IMRIS's VISIUS Surgical Theatres are designed to support a range of medical applications, primarily focusing on neurosurgical, spinal, cerebrovascular, and cardiovascular interventions. By bringing advanced imaging capabilities into the OR, IMRIS aims to improve surgical outcomes, reduce the need for repeat procedures, and enhance patient safety. The company's solutions are sold to hospitals and medical centers worldwide, providing them with the tools to deliver cutting-edge clinical services. In addition to its VISIUS Surgical Theatre, IMRIS provides ongoing service and extended maintenance contracts to ensure the continued performance and reliability of its systems. The company also offers a range of accessories and disposables to support the use of its imaging technologies. With a focus on innovation and clinical excellence, IMRIS seeks to advance the field of image-guided therapy and improve the lives of patients around the world.

Ne Yaparlar

  • Designs and manufactures image-guided therapy solutions.
  • Offers VISIUS Surgical Theatres, integrating MRI, CT, and fluoroscopy into surgical suites.
  • Provides intraoperative vision to clinicians for enhanced surgical precision.
  • Sells VISIUS Surgical Theatres to hospitals for neurosurgical, spinal, cerebrovascular, and cardiovascular markets.
  • Offers service and extended maintenance contracts.
  • Provides accessories and disposables for its imaging systems.

İş Modeli

  • Sells VISIUS Surgical Theatres to hospitals and medical centers.
  • Generates revenue through service and extended maintenance contracts.
  • Sells accessories and disposables related to its imaging systems.

Sektör Bağlamı

IMRIS Inc. operates within the medical specialties sector, which is characterized by technological advancements and increasing demand for minimally invasive surgical procedures. The integration of advanced imaging technologies into surgical environments is a growing trend, driven by the need for greater precision and improved patient outcomes. The competitive landscape includes companies like AMPE, BLMS, BTTX, CENBF, and DMSI, which offer various medical imaging and surgical solutions. The market for image-guided therapy is expected to grow, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in imaging technologies.

Kilit Müşteriler

  • Hospitals that deliver clinical services to patients.
  • Medical centers specializing in neurosurgery, spinal surgery, cerebrovascular surgery, and cardiovascular surgery.
  • Healthcare providers seeking advanced intraoperative imaging solutions.
AI Güveni: 71% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

IMRIS Inc. (IMRSQ) hisse senedi fiyatı: Price data unavailable

Son Haberler

IMRSQ için son haber bulunmamaktadır.

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

IMRSQ için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

IMRSQ için Wall Street fiyat hedefi analizi.

MoonshotScore

46/100

Bu puan ne anlama geliyor?

MoonshotScore, IMRSQ'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Shalabh Chandra

CEO

Shalabh Chandra serves as the CEO of IMRIS Inc., leading a team of 121 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background cannot be provided. However, as CEO, he is responsible for the overall strategic direction and operational performance of the company.

Sicil: Due to the limited information available, it is not possible to provide a detailed track record of Shalabh Chandra's achievements and strategic decisions at IMRIS Inc. or in previous roles. His tenure at the company cannot be determined from the provided data.

IMRSQ OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that IMRIS Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be subject to greater risks. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, OTC Other stocks are not subject to stringent listing requirements, leading to increased potential for volatility and information asymmetry. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Given that IMRIS Inc. trades on the OTC Other market, liquidity is likely to be limited. This can result in wider bid-ask spreads and greater difficulty in buying or selling shares without significantly impacting the price. Low trading volume can also increase volatility, making it challenging for investors to execute large trades. Investors should be prepared for potential delays and price fluctuations when trading IMRSQ shares.
OTC Risk Faktörleri:
  • Limited financial disclosure increases information asymmetry.
  • Low trading volume and liquidity can lead to price volatility.
  • OTC Other stocks are subject to less regulatory oversight.
  • Potential for fraud or manipulation is higher in the OTC market.
  • Company may not meet minimum financial standards for higher exchange listings.
Durum Tespiti Kontrol Listesi:
  • Verify the company's registration and legal standing.
  • Assess the availability and reliability of financial information.
  • Research the background and experience of the company's management team.
  • Analyze the company's business model and competitive landscape.
  • Evaluate the company's financial performance and solvency.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Meşruiyet Sinyalleri:
  • Company has been in operation since 2005.
  • Focuses on a specialized niche market in image-guided therapy.
  • Offers a tangible product (VISIUS Surgical Theatre).
  • Has a team of 121 employees.

IMRSQ Hakkında Sıkça Sorulan Sorular

IMRSQ için değerlendirilmesi gereken temel faktörler nelerdir?

IMRIS Inc. (IMRSQ) şu anda yapay zeka skoru 46/100, düşük puanı gösteriyor. Temel güçlü yan: Innovative VISIUS Surgical Theatre technology.. İzlenmesi gereken birincil risk: Ongoing: Negative profit margin raises concerns about financial sustainability.. Bu bir finansal tavsiye değildir.

IMRSQ MoonshotScore'u nedir?

IMRSQ şu anda MoonshotScore'da 46/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

IMRSQ verileri ne sıklıkla güncellenir?

IMRSQ fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler IMRSQ hakkında ne diyor?

IMRSQ için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

IMRSQ'a yatırım yapmanın riskleri nelerdir?

IMRSQ için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Negative profit margin raises concerns about financial sustainability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

IMRSQ'ın P/E oranı nedir?

IMRSQ için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için IMRSQ'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

IMRSQ aşırı değerli mi, yoksa düşük değerli mi?

IMRIS Inc. (IMRSQ)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

IMRSQ'ın temettü verimi nedir?

IMRIS Inc. (IMRSQ) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Limited information available for certain sections, particularly CEO background and track record.
  • OTC market stocks carry higher risk than exchange-listed stocks.
Veri Kaynakları

Popüler Hisseler